Trial record 1 of 1 for:    NCT02548351
Previous Study | Return to List | Next Study

Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02548351
Recruitment Status : Recruiting
First Posted : September 14, 2015
Last Update Posted : December 10, 2018
Information provided by (Responsible Party):
Intercept Pharmaceuticals

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : October 2022
  Estimated Study Completion Date : October 2022